IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0446235
(2007-10-15)
|
등록번호 |
US-8524254
(2013-09-03)
|
우선권정보 |
GB-0620685.8 (2006-10-18) |
국제출원번호 |
PCT/GB2007/003936
(2007-10-15)
|
§371/§102 date |
20100323
(20100323)
|
국제공개번호 |
WO2008/047100
(2008-04-24)
|
발명자
/ 주소 |
- Nicolson, Donald Magnus
- Halliday, Janet Anne
- Tuominen, Jukka
- Zurutuza, Amaia
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
264 |
초록
▼
A bioresorbable polymer is obtained by reacting together (a) a prepolymer comprising co-polymerised units of a caprolactone and poly(alkylene oxide) moieties; (b) a polycaprolactone diol comprising co-polymerised units of a caprolactone and a C2-C6 diol; and (c) a diisocyanate. The polymer may be lo
A bioresorbable polymer is obtained by reacting together (a) a prepolymer comprising co-polymerised units of a caprolactone and poly(alkylene oxide) moieties; (b) a polycaprolactone diol comprising co-polymerised units of a caprolactone and a C2-C6 diol; and (c) a diisocyanate. The polymer may be loaded with a pharmaceutically active agent to produce a drug delivery device.
대표청구항
▼
1. A polymer obtained by reacting together: (a) a prepolymer comprising co-polymerised units of a caprolactone and poly(alkylene oxide) moieties;(b) a polycaprolactone diol comprising co-polymerised units of a caprolactone and a C2-C6 diol, the C2-C6 diol having a lower molecular weight than the pol
1. A polymer obtained by reacting together: (a) a prepolymer comprising co-polymerised units of a caprolactone and poly(alkylene oxide) moieties;(b) a polycaprolactone diol comprising co-polymerised units of a caprolactone and a C2-C6 diol, the C2-C6 diol having a lower molecular weight than the poly(alkylene oxide) of prepolymer (a); and(c) a diisocyanate;wherein the molar ratio of component (a) to component (b) to component (c) is in the range of about 0.15-1.5 to about 1.0 to about 1.0-2.75 and the polymer is a linear polymer. 2. The polymer according to claim 1, wherein the poly(alkylene oxide) of prepolymer (a) is a poly (C2-C3 alkylene oxide) or mixture thereof. 3. The polymer according to claim 1, wherein the poly(alkylene oxide) is poly(ethylene glycol). 4. The polymer according to claim 3, wherein the poly(ethylene glycol) has the structure HO(CH2CH2O)nH wherein n is an integer from 1 to 800. 5. The polymer according to claim 3, wherein the poly(ethylene glycol) has an average molecular weight of 300 g/mol to 10,000 g/mol. 6. The polymer according to claim 5 wherein the poly(ethylene glycol) has an average molecular weight of 400 g/mol to 10,000 g/mol. 7. The polymer according to claim 1, wherein prepolymer (a) is a block copolymer of structure (CAP)n-PEG-(CAP)n, where CAP is caprolactone and PEG is polyethylene glycol; and n in each CAP block is from 3 to 40. 8. The polymer according to claim 7 wherein n is from 5 to 31. 9. The polymer according to claim 3 wherein molar ratio of caprolactone to poly(ethylene glycol) in prepolymer (a) is from 2:1 up to 124:1. 10. The polymer according to claim 1, wherein the polymer is obtained by reacting components (a), (b), and (c) together with a polymerisation catalyst, wherein the polymerisation catalyst is stannous octoate. 11. The polymer according to claim 1 wherein the C2-C6 diol of component (b) has the structure HO—(CH2)m—OH wherein m is from 2 to 6. 12. The polymer according to claim 1 wherein the C2-C6 diol of component (b) is a poly(ethylene oxide). 13. The A polymer according to claim 1 wherein the C2-C6 diol of component (b) is ethylene glycol and the molar ratio of caprolactone to ethylene glycol in component (b) is 4 or 2. 14. The A polymer according to claim 1 wherein the diisocyanate (c) is 1,6-hexamethylene diisocyanate or L-Iysine diisocyanate. 15. The polymer according to claim 1 wherein the diisocyanate (c) is 1,4-butane diisocyanate. 16. A delivery device, which comprises the polymer of claim 1 loaded with an active agent. 17. The drug delivery device according to claim 16, wherein the active agent is a pharmaceutically active agent. 18. A method for preparing the polymer of claim 1, which comprises reacting together components (a), (b) and (c). 19. A pharmaceutical composition, comprising the polymer of claim 1 and a releasable pharmaceutically active agent. 20. The composition of claim 19, where in the composition is in a solid dosage form. 21. The polymer of claim 1, wherein the molar ratio of component (a) to component (b) to component (c) is in the range of about 0.2-1.0 to about 1.0 to about 1.25-2.5. 22. The polymer of claim 1, wherein the molar ratio of component (a) to component (b) to component (c) is in the range of about 0.25-1.0 to about 1.0 to about 2.5. 23. The delivery device of claim 16, wherein the poly(alkylene oxide) of prepolymer (a) is a poly (C2-C3 alkylene oxide) or mixture thereof. 24. The delivery device of claim 23, wherein the poly(alkylene oxide) is poly(ethylene glycol). 25. The delivery device of claim 24, wherein the poly(ethylene glycol) has the structure HO(CH2CH2O)nH, in which is an integer from 1 to 800. 26. The delivery device of claim 24, wherein the poly(ethylene glycol) has an average molecular weight of 300 g/mol to 10,000 g/mol. 27. The delivery device of claim 26, wherein the poly(ethylene glycol) has an average molecular weight of 400 g/mol to 10,000 g/mol. 28. The delivery device of claim 16, wherein prepolymer (a) is a block copolymer of structure (CAP)n-PEG-(CAP)n, where CAP is caprolactone and PEG is polyethylene glycol; and n in each CAP block is from 3 to 40. 29. The delivery device of claim 28, wherein n is from 5 to 31. 30. The delivery device of claim 24, wherein molar ratio of caprolactone to poly(ethylene glycol) in prepolymer (a) is from 2:1 up to 124:1. 31. The delivery device of claim 16, wherein the polymer is obtained by reacting components (a), (b), and (c) together with a polymerisation catalyst, wherein the polymerisation catalyst is stannous octoate. 32. The delivery device of claim 16, wherein the C2-C6 diol of component (b) has the structure HO—(CH2)m—OH, in which m is from 2 to 6. 33. The delivery device of claim 16, wherein the C2-C6 diol of component (b) is a poly(ethylene oxide). 34. The delivery device of claim 16, wherein the C2-C6 diol of component (b) is ethylene glycol and the molar ratio of caprolactone to ethylene glycol in component (b) is 4 or 2. 35. The delivery device of claim 16, wherein the diisocyanate (c) is 1,6-hexamethylene diisocyanate or L-Iysine diisocyanate. 36. The delivery device of claim 16, wherein the diisocyanate (c) is 1,4-butane diisocyanate. 37. The delivery device of claim 16, wherein the molar ratio of component (a) to component (b) to component (c) is in the range of about 0.2-1.0 to about 1.0 to about 1.25-2.5. 38. The delivery device of claim 16, wherein the molar ratio of component (a) to component (b) to component (c) is in the range of about 0.25-1.0 to about 1.0 to about 2.5.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.